6G4.2.5 (ATCC® HB-11722)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Storage Conditions liquid nitrogen vapor phase
Images
Derivation
An expression plasmid p6G425chim2 (ATCC 97055) was created to code for a chimeric murine-human Fab fragment of the monoclonal antibody. Cell lines producing the recombinant humanized antibody are available (ATCC CRL-12444 and ATCC CRL-12445)
Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against rabbit interleukin 8 (IL-8)
Comments
An expression plasmid p6G425chim2 (ATCC 97055) was created to code for a chimeric murine-human Fab fragment of the monoclonal antibody. Cell lines producing the recombinant humanized antibody are available (ATCC CRL-12444 and ATCC CRL-12445)
Animals were immunized with rabbit interleukin 8 (IL-8).
Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells.
The antibody blocks IL-8 binding to rabbit neutrophil receptors.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10 exp6 cells/ml.
Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Evey 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG2a kappa , IgG2a
Name of Depositor Genentech, Inc.
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000